Dabigatran is an inferior thromboembolism prophylactic treatment compared to enoxaparin .
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
J Arthroplasty. 2009 Jan;24(1):1-9. Epub 2008 Apr 141896 patients scheduled to undergo total knee arthroplasty were randomized to one of three thromboembolism prophylaxis treatments to determine the best prophylaxis option. Patients either received an oral 220 mg dose of dabigatran once daily, an oral 150 mg dose of dabigatran once daily, or a 30 mg injection of enoxaparin twice daily. The results from this study indicated that both treatments of dabigatran were inferior in comparison to the standard enoxaparin in prevention of venous thromboembolism (VTE).
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
